CoChat

SUBRETINAL FIBROSIS AFTER ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY IN EYES WITH MYOPIC CHOROIDAL NEOVASCULARIZATION

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Abstract

In Brief Purpose: To assess the incidence and risk factors of subretinal fibrosis and their impact on visual outcome in eyes with myopic CNV. Methods: Medical records of 72 eyes treated with antivascular endothelial growth factor (anti-VEGF) therapy in a pro re nata regimen for myopic CNV that followed up for more than 1 year were retrospectively reviewed. The presence of subretinal fibrosis after anti-VEGF therapy was determined using both fundus photographs and optical coherence tomography. The incidence and risk factors of subretinal fibrosis were evaluated, and best-corrected visual acuity was compared between the eyes with and without subretinal fibrosis. Results: The incidences of subretinal fibrosis during the 1-year and whole follow-up period were 31.9% and 36.1%, respectively. Occurrence of subretinal fibrosis was associated with frequent CNV recurrence (P = 0.005) and poor baseline best-corrected visual acuity (P = 0.044) in a Cox proportional hazard model. Anatomically, the eyes with subretinal fibrosis showed more frequent progression of chorioretinal atrophy (95.7% vs. 71.4%, P = 0.027) and less frequent photoreceptor recovery (17.4% vs. 65.3%, P < 0.001) after anti-VEGF therapy. Occurrence of subretinal fibrosis was associated with poor vision at baseline (P = 0.011) and the final visit (P = 0.008) when compared with the findings in the nonoccurrence group. Conclusion: Development of subretinal fibrosis after anti-VEGF therapy was common in eyes with myopic CNV and was associated with CNV recurrence. Myopic eyes with subretinal fibrosis show progressive chorioretinal atrophy and poor visual outcome. Subretinal fibrosis occurs in approximately one third of eyes with myopic choroidal neovascularization (CNV) after antivascular endothelial growth factor therapy. Subretinal fibrosis leads to more frequent progression of chorioretinal atrophy, less frequent photoreceptor recovery, and poor visual outcomes. Choroidal neovascularization recurrence is associated with the development of subretinal fibrosis.

Overview

Integrity signals

Registry

Crossref · 10.1097/iae.0000000000001043

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 32 references

Cited by

See all 26

Metadata

Authors
Ahn, S. J., Park, K. H., & Woo, S. J.
Affiliations
Seoul National University Bundang Hospital (KR)
Venue
Retina
Published
2016-11
Volume
36
Issue
11
Pages
2140-2149
ISSN
0275-004X (ISSN-L)
OpenAlex
W2342491423
Cited by
25
References
32
Citations by year
2026: 3 · 2025: 5 · 2024: 1 · 2022: 5 · 2021: 2 · 2020: 2 · 2019: 1 · 2018: 3 · 2017: 3
FWCI
2.48
Type
journal article
Language
en
Open access
closed
Locations
  • Retina (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
  • Health Sciences › Medicine › Ophthalmology › Retinal and Macular Surgery
  • Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
Keywords
subretinal fibrosis, myopic choroidal neovascularization, anti-VEGF therapy, pro re nata regimen, chorioretinal atrophy, photoreceptor recovery, best-corrected visual acuity, risk factors, visual outcome
MeSH terms
Bevacizumab, Ranibizumab, Adult, Aged, Female, Fibrosis, Humans, Male, Middle Aged, Photography, Retina, Retrospective Studies, Risk Factors, Visual Acuity, Incidence, Choroidal Neovascularization, Angiogenesis Inhibitors, Tomography, Optical Coherence, Vascular Endothelial Growth Factor A, Myopia, Degenerative

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: SUBRETINAL FIBROSIS AFTER ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY IN EYES WITH MYOPIC CHOROIDAL NEOVASCULARIZATION. https://app.cochat.ai/papers/10.1097/iae.0000000000001043
The paper
Ahn, S. J., Park, K. H., & Woo, S. J. (2016). SUBRETINAL FIBROSIS AFTER ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY IN EYES WITH MYOPIC CHOROIDAL NEOVASCULARIZATION. Retina. https://doi.org/10.1097/iae.0000000000001043

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.